Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study

Current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis slow down disease progression but have little impact on symptoms or quality of life in patients. This study was conducted to evaluate the effects of systemic enzymes in relieving symptoms associated with PF and improving...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Neha Shah
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pulmonary fibrosis idiopathic pulmonary fibrosis dietary supplements systemic enzyme therapy health related quality of life Medicine R
Acceso en línea:	https://doaj.org/article/0c23c85ee63a4396a8b3d0df3234332a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c23c85ee63a4396a8b3d0df3234332a
record_format	dspace
spelling	oai:doaj.org-article:0c23c85ee63a4396a8b3d0df3234332a2021-11-25T18:19:21ZEffects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study10.3390/medicines81100682305-6320https://doaj.org/article/0c23c85ee63a4396a8b3d0df3234332a2021-11-01T00:00:00Zhttps://www.mdpi.com/2305-6320/8/11/68https://doaj.org/toc/2305-6320Current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis slow down disease progression but have little impact on symptoms or quality of life in patients. This study was conducted to evaluate the effects of systemic enzymes in relieving symptoms associated with PF and improving quality of life. Methods: an open-label, prospective study on subjects with a confirmed diagnosis of PF was conducted as proof-of-concept. The subjects (<i>n</i> = 13) received the oral systemic enzyme supplements Serracor-NK and Serra Rx for 12 weeks and completed Health-Related Quality of Life (HRQL) questionnaires. The effect of this regimen was examined by comparing the end-of-treatment questionnaire scores with baseline values. Results: significant improvement was seen in 61.5% of subjects, as assessed by the WHO well-being index; an improvement in scores was seen in 84.6% of the subjects, as assessed by the UCSD Shortness of Breath Questionnaire, with 38.4% of the subjects showing minimal clinically important difference; the supplementation was found to be efficacious in 69.2%, 84.6%, 69.2% and 61.5% of the subjects, as assessed by the Saint George’s Respiratory Questionnaire total, symptom, activity, and impact scores, respectively. Conclusions: Serracor-NK and Serra Rx improve symptoms, as well as mental and physical wellbeing and HRQL in patients with PF.Neha ShahMDPI AGarticlepulmonary fibrosisidiopathic pulmonary fibrosisdietary supplementssystemic enzyme therapyhealth related quality of lifeMedicineRENMedicines, Vol 8, Iss 68, p 68 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pulmonary fibrosis idiopathic pulmonary fibrosis dietary supplements systemic enzyme therapy health related quality of life Medicine R
spellingShingle	pulmonary fibrosis idiopathic pulmonary fibrosis dietary supplements systemic enzyme therapy health related quality of life Medicine R Neha Shah Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study
description	Current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis slow down disease progression but have little impact on symptoms or quality of life in patients. This study was conducted to evaluate the effects of systemic enzymes in relieving symptoms associated with PF and improving quality of life. Methods: an open-label, prospective study on subjects with a confirmed diagnosis of PF was conducted as proof-of-concept. The subjects (<i>n</i> = 13) received the oral systemic enzyme supplements Serracor-NK and Serra Rx for 12 weeks and completed Health-Related Quality of Life (HRQL) questionnaires. The effect of this regimen was examined by comparing the end-of-treatment questionnaire scores with baseline values. Results: significant improvement was seen in 61.5% of subjects, as assessed by the WHO well-being index; an improvement in scores was seen in 84.6% of the subjects, as assessed by the UCSD Shortness of Breath Questionnaire, with 38.4% of the subjects showing minimal clinically important difference; the supplementation was found to be efficacious in 69.2%, 84.6%, 69.2% and 61.5% of the subjects, as assessed by the Saint George’s Respiratory Questionnaire total, symptom, activity, and impact scores, respectively. Conclusions: Serracor-NK and Serra Rx improve symptoms, as well as mental and physical wellbeing and HRQL in patients with PF.
format	article
author	Neha Shah
author_facet	Neha Shah
author_sort	Neha Shah
title	Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study
title_short	Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study
title_full	Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study
title_fullStr	Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study
title_full_unstemmed	Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study
title_sort	effects of systemic enzyme supplements on symptoms and quality of life in patients with pulmonary fibrosis—a pilot study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0c23c85ee63a4396a8b3d0df3234332a
work_keys_str_mv	AT nehashah effectsofsystemicenzymesupplementsonsymptomsandqualityoflifeinpatientswithpulmonaryfibrosisapilotstudy
_version_	1718411301879808000

Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study

Ejemplares similares